Aetiologic and predisposing factors are still controversial about Peyronie’s disease (PD). However, it is thought to be the result of connective tissue disorder or healing defect. Androgens are known to affect collagen metabolism and wound healing in the body.
Botulinum toxin injection has been widely accepted by the urology and urogynecology medical communities as a safe and effective treatment for refractory urinary incontinence. There are two approved genitourinary indications for botulinum toxin.
Neurogenic lower urinary tract dysfunction (NULTD) is common in patients with multiple sclerosis (MS); nevertheless, it is often underestimated, underdiagnosed, and undertreated due to patients’ sense of shame, variability of symptoms, as well as lack of communication between neurologists and urologists, despite the availability of several guidelines based on scientific evidence and expert opinion.
Overactive bladder (OAB) and frailty are multidimensional syndromes, and the prevalence of both increases with age. Little evidence exists for a direct association between OAB and frailty, but urinary urgency may well be a precursor of frailty in older people.
Our objectives are to (1) identify predictors of treatment success in women with overactive bladder (OAB) after 1 year of percutaneous tibial nerve stimulation (PTNS) maintenance therapy, (2) identify trends in success rates during that 1 year, and (3) assess maintenance treatment adherence.
To evaluate the efficacy and safety of collagenase Clostridium histolyticum (CCH) for the management of penile deformities in patients presenting with different categories of atypical Peyronie’s disease (PD).
(UroToday.com) At the AUA 2020 virtual annual meeting, Sam Chang, MD, MBA, moderated a case-based panel discussion on both non-muscle and muscle-invasive bladder cancer. Areas of focus for this discussion included (i) CIS, (ii) T1 bladder cancer, (iii) multimodality therapy for invasive disease, and (iv) advances for metastatic bladder cancer.
(UroToday.com) At the 2020 Virtual American Urological Association (AUA) annual meeting’s International Prostate Forum, Dr. James Gulley discussed implications of the genomic analysis for patients with metastatic castration-resistant prostate cancer (mCRPC) and why precision medicine for these patients matters. The role of genomic testing is to identify risk factors and prognostic factors (in healthy people or […]
(UroToday.com) Despite active surveillance being the preferred management option for low-risk prostate cancer, formal guidelines on optimal follow-up are inconsistent and practices vary considerably across treatment centers. At the American Urological Association (AUA) 2020 virtual annual meeting, Dr. Monique Roobol and colleagues presented results of their study describing the risk of upgrading and conversion to […]
(UroToday.com) The safety of active surveillance for grade group 2 patients is debated, in that it has been evaluated in several single-center studies with mixed results.1-2 At the American Urological Association (AUA) annual virtual meeting, Dr. Adrian J. Waisman Malaret and colleagues presented results of their study assessing the clinical outcomes of men with grade group […]
